NCT00818831Unknown1 期
Phase I Safety and Pharmacokinetic Study of QBI-139 Injection Administered by Weekly Intravenous Infusion in Patients With Refractory Malignancies
适应症
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 30
- 试验地点
- 3
- 主要终点
- To evaluate the toxicity and tolerability of and the maximum tolerated dose for QBI-139 in patients with advanced refractory solid tumors.
研究概览
简要总结
The purposes of this trial are:
- To evaluate the toxicity and tolerability of QBI-139 in patients with advanced refractory solid tumors.
- To determine the maximum tolerated dose of QBI-139 in patients with advanced, refractory solid tumors.
Patients will receive QBI-139 by IV infusion over at least one hour once weekly for three weeks. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3 to 6 patients receive escalating doses of QBI-139 until the maximum tolerated dose (MTD) is determined.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must be refractory to or intolerant of established therapy known to provide clinical benefit for their condition, i.e., patients must not be candidates for regimens known to provide clinical benefit.
- •Patients must have measurable (as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria) solid tumors.
- •Prior chemotherapy and radiation therapy are allowed (at least 4 weeks must have passed from prior chemotherapy and radiotherapy (6 weeks for nitrosoureas or mitomycin C)), provided that clinically significant toxicity related to prior chemotherapy or radiotherapy has returned to baseline or National Cancer Institute (NCI) Common Toxicity and Adverse Events (CTCAE) grade ≤ 2 and are not expected to recover further. The toxicities specifically exclude alopecia.
- •Age >18 years.
- •ECOG performance status <
- •Life expectancy of greater than 12 weeks, as estimated by Principal Investigator.
- •Patients must have normal organ and marrow function as defined in the protocol.
- •The effects of QBI-139 on the developing human fetus are unknown. Therefore, both men and women should not attempt to conceive and women should not be pregnant or breast-feeding while taking part in this study (or for 90 days after completing the study).
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Concurrent treatment with an investigational agent other than the investigational agent(s) used in this study OR treatment within 4 weeks of study entry with any investigational agent(s) or device(s).
- •Failure to recover fully (as judged by the Investigator) from prior surgical procedures.
- •Patients with known brain metastases or leptomeningeal carcinomatosis
- •Patients who have had a gastrointestinal bleed requiring transfusion within the past 6 months or active Grade 2 or higher diarrhea
- •Treatment with Ranpirnase (Onconase®)
- •Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Women who are pregnant or breastfeeding
- •Patients known to have HIV are ineligible
- •Patients with known immunocompromised status or organ transplants will be excluded
- •Patients must not have:
- •unstable angina (anginal symptoms at rest) within the past 6 months or
- •myocardial infarction within the past 6 months or
- •new onset angina within the last 3 months.
- •QT prolongation (defined as QTc >450 msec for males and QTc >470 msec for females)
结局指标
主要结局
To evaluate the toxicity and tolerability of and the maximum tolerated dose for QBI-139 in patients with advanced refractory solid tumors.
时间窗: Cycle 1 (three weeks)
次要结局
- To determine the patient response rate to QBI-139 using the RECIST criteria.(Duration of drug administration)
- To evaluate the pharmacokinetics of QBI-139(Cycles 1 and 2 (six weeks))
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With ChloroquineMalariaNCT00323375Tulane University Health Sciences Center122
已完成
1 期
This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 1358894 Affects the Way the Body Breaks Down MidazolamHealthyNCT03754959Boehringer Ingelheim50
终止
1 期
This Study Tests How Different Doses of BI 1291583 Are Taken up in the Body and How Well They Are ToleratedHealthyNCT03414008Boehringer Ingelheim54
招募中
1 期
A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.Advanced Solid TumorNCT06298058Shanghai Institute Of Biological Products144
已完成
1 期
This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the BloodHealthyNCT03210272Boehringer Ingelheim83